Kadimastem Appoints Ruth Alon as Chairperson of the Company's Board of Directors

Ruth Alon is a leading figure in the venture capital, life sciences industry in Israel; she is replacing Dr. Eli Opper, who resigned after 10 years as Company Chairman of the Board

Ms. Ruth Alon said: "I am delighted to join Kadimastem’s Board of Directors. The Company is now at an exciting phase, as it has recently demonstrated clinical progress in its ALS program and significant preclinical achievements with its cell product intended for the treatment of Insulin Dependent Diabetes. I believe that the combination of experienced and committed management together with the science behind the Company's unique technology can put Kadimastem at the forefront of cellular therapy. I look forward to collaborating with the team and contributing to their success."

NESS ZIONA, ISRAEL May 19th 2020 – Kadimastem Ltd. (TASE: KDST), a clinical stage cell therapy company announces the appointment of Ms. Ruth Alon as Chairperson of the Company's Board of Directors. Dr. Eli Opper who served as Chairman of the Board throughout the past ten years has resigned for personal reasons.

Ms. Alon is a key leader in the venture capital, life sciences, healthcare and medical devices industries in Israel, with over 35 years of expertise, knowhow and business management experience. Ms. Alon is the Founder and CEO of Medstrada; a company established in 2018, providing consulting services to the healthcare and food-tech industries. Ms. Alon also served as General Partner at the Pitango Venture Capital Fund and headed the Life Sciences sector. Among other things, Ms. Alon lead portfolio companies to successful acquisitions, including Disc-O-Tech, Colbar, Ventor and Optonol, where she served as a director. Ms. Alon currently serves as a director in many companies in the Healthcare Industry, including: Brainsgate, Carbofix Orthopedics, Vascular Biogenics (VBLT), Anchiano Therapeutics (ANCN) which are traded on Nasdaq, as well as a Director at BioRap, Tech Transfer Office of the Rappaport Institute, Technion.

Rami Epstein, CEO of Kadimastem, said: "We are pleased to announce Ruth Alon's joining of Kadimastem as Chairperson of the Company's Board of Directors and we consider it a show of strong confidence in our Company, management and our business strategy to become a leading player in the cellular therapy industry. As one of the more prominent and valued business persons in the Life Science industry and Venture Capitals in Israel, I have no doubt that Ruth’s experience and knowledge will greatly contribute to advancing our clinical and commercial / business plans and strengthen the Company's relationship with the global pharmaceutical industry. I would like to deeply thank Dr. Eli Opper for his care and contribution to the Company as the Chairman of the Board".

Ms. Alon previously worked on Wall Street, between 1981-1997, where she served as a senior medical device analyst at Montgomery Securities Investment Bank as well as at Kidder Peabody & Co. Investment Bank. In addition, Ms. Alon initiated and led the establishment in 2005, of ILSI (the Israeli Life Sciences Industry Association), a non-profit organization representing the common goals of approximately 1,200 Israeli life sciences companies. Ms. Alon is also the co-founder of IATI, (the Israeli Advanced Industries Association), the umbrella organization of the high-tech, life sciences and other advanced industries in Israel, established in 2012. Ms. Alon holds a B.A. in Economics from the Hebrew University of Jerusalem, an M.B.A. in business administration from Boston University and an M.Sc. from Columbia University, School of Physicians and Surgeons.

Company Contacts:

Yossi Nizhar, CFO


Global Media & Collaborations

Dasy Mandel, Director of Business Development


© 2020 by Kadimastem

  • White Facebook Icon
  • White Twitter Icon
  • White LinkedIn Icon